Table 1. Patient and disease characteristics of the MPC cohort.
| Characteristics | MPC cohort (n=37) | Historical (n=171) | P-valuea |
|---|---|---|---|
| Age, median (range) | 62 (50–77) | 61 (25–76) | 0.75b |
| Male, n (%) | 21 (56.8) | 106 (62) | 0.58c |
| ECOG PS, n (%) | 0.47c | ||
| 0 | 17 (46.0) | 64 (37.4) | |
| 1 | 20 (54.0) | 106 (62.0) | |
| Pancreatic tumour location, n/total no. (%)d | |||
| Head | 17/31 (54.8) | 67/165 (40.6) | 0.58c |
| Body | 14/31 (45.2) | 98/165 (59.4) | |
| Metastatic sites, n/total no. (%) | |||
| Liver | 20/37 (54.1) | 149/170 (87.6) | <0.0001c |
| Peritoneal | 14/37 (37.8) | 33/170 (19.4) | 0.010c |
| Lung | 12/37 (32.4) | 33/170 (19.4) | 0.059c |
| Lymph node | 15/37 (40.5) | 49/170 (28.8) | 0.145c |
| Level of CA19.9, n/total no. (%) | 0.85** | ||
| Normal | 4/37 (10.8) | 24/164 (14.6) | |
| Elevated,<59 × ULN | 18/37 (48.7) | 72/164 (43.9) | |
| Elevated,⩾59 × ULN | 15/37 (40.5) | 68/164 (41.5) | |
| Biliary stent, n/total no. (%) | 0.23c | ||
| Yes | 9/37 (24.3) | 27 (15.8) | |
| No | 28/37 (75.7) | 144 (84.2) | |
a
Comparison between evaluable patients in the MPC cohort and the historical control group treated with standard FOLFIRINOX as reported by Conroy et al.
b
P-value from one sample median test (signed-rank test).
c
P-value is based on Fisher exact test for count.
d
Six patients had prior pancreatic resection.